about
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.The aged patient with lung cancer. Management recommendations.Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients.Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.Comment on "repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results": will there be clinical implications in the future?Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT) for the salvage treatment of esophageal carcinoma following trimodality therapy: a case report.Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study.Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot studyEvaluation of Two Consecutive Regimens in Advanced Gastric CancerBuserelin treatment of advanced prostatic cancer: A phase II studyLow-Dose Aminoglutethimide Plus Steroid Replacement in Advanced Breast Cancer Patients Resistant to Conventional TherapiesCisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: A phase II studyCombination chemotherapy with fluorouracil, adriamycin, cis-Platinum and VM-26 in advanced transitional cell carcinoma of the urinary tractPhase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patientsSafety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient ProgrammeNegative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access programPhase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and TreatmentPhase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumorClinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger
P50
Q33391020-8CBC484E-DEBA-4E0A-80BB-A36C47780DF3Q33413133-7024F7AC-736B-45F7-A07F-EC255027DF34Q33417698-7D2AC684-5F2B-454D-A09A-00434FE9F2CBQ33419797-802BC999-19D0-4285-9337-F0980365D925Q33429261-7C711C45-0F6D-4562-B64D-972776DB7AF4Q34351372-5A8587F1-98AA-4D74-A1F6-7CA3C48B5837Q34660431-4EC86233-F086-480B-A2BB-0394ACB7B60EQ36915163-F4777F92-4110-4AE4-955E-5DC5F66B5582Q37429996-44E963B6-0FE9-41A5-A400-FB8F2A5AD094Q38317759-8D8A5DAA-4284-47ED-BE48-941645A2D995Q38699712-E6056C65-3D65-4C82-AB0F-E8F9DFE3FE63Q38956775-FE137809-E4EB-426D-A012-3D56F2799C6BQ39030381-64C371DE-6510-42FB-AF74-543D651C569FQ39087452-E9FD6F64-D685-4255-A1E2-102736E7302FQ40406176-AC8ED49E-DF8D-42BF-BE6B-7F36F93AFE07Q40527144-2543963C-A514-497B-9BAF-072A55D8386EQ40725993-C69F77F8-92AD-43C5-A4ED-ED20A502F808Q40811026-2AAE0C65-BD69-4FFD-9017-5EC40B912B15Q41746316-574D4D26-72AC-4051-96E1-1D381E431E03Q43918783-5E59363F-A8C5-4D06-A5DD-B7B75140983DQ44801543-E2B774A0-81C5-4E90-A8BD-7BAEBABA4914Q45986050-1E3F0DD2-BEAD-4C98-B179-546570A9DA75Q47218550-17ECD486-78AC-4F81-84A7-4C131C864F50Q51443498-D409F518-FE13-4730-A96F-5EC98DD03063Q53128779-86D6743C-1DBC-4068-9D01-725D0247CF4EQ54368832-9D2D043B-3050-4A57-9B5A-E3441AB15FDEQ60685454-405AEE8E-944D-45D0-86A1-B3E10AE38275Q60685507-E57658E7-E5BA-4B9C-AE1C-74969069843BQ60685527-09EA3ABD-C04C-4D45-A749-7378562FCCB1Q60685534-91A86F21-E891-41A4-8989-854CE79E8BA9Q60685545-B963893F-AE90-47D9-96CC-8F06CDCA7399Q60685553-80A78397-6BFF-4A38-90BD-17AD59CA2F7AQ60697885-12C99837-8BC4-408C-A5DE-E11F85736819Q61447523-579D04D0-1DB4-4E08-BE38-28BAAD55EF35Q62661811-A6E1352D-6A39-4C0D-8EA8-109C8E88DBC0Q80025874-5D94EA2B-933F-4B38-AD5F-7BA74FAF2B22Q83937058-9ABFC716-488E-49B0-871B-4442E8E979B8Q87176751-34C33DC4-BFC3-45BF-A735-947CC846B95F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giovanni Lo Re
@ast
Giovanni Lo Re
@en
Giovanni Lo Re
@es
Giovanni Lo Re
@nl
type
label
Giovanni Lo Re
@ast
Giovanni Lo Re
@en
Giovanni Lo Re
@es
Giovanni Lo Re
@nl
prefLabel
Giovanni Lo Re
@ast
Giovanni Lo Re
@en
Giovanni Lo Re
@es
Giovanni Lo Re
@nl
P106
P1153
6701871947
P21
P31
P496
0000-0003-1169-2359